Analyst Ratings For OpGen Inc (NASDAQ:OPGN)
Today, HC Wainwright set its price target on OpGen Inc (NASDAQ:OPGN) to $6.00 per share.
There are 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on OpGen Inc (NASDAQ:OPGN) is Buy with a consensus target price of $6.00 per share, a potential 453.00% upside.
Some recent analyst ratings include
- 6/19/2017-OpGen Inc (NASDAQ:OPGN) had its Buy rating reiterated by Dawson James
- On 7/18/2017 Jven Capital, Llc, Chairman, bought 1,875,000 with an average share price of $0.40 per share and the total transaction amounting to $750,000.00.
- On 7/18/2017 Timothy C Dec, CFO, bought 65,000 with an average share price of $0.40 per share and the total transaction amounting to $26,000.00.
About OpGen Inc (NASDAQ:OPGN)
OpGen, Inc., a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel in vitro diagnostic test designed to detect bacterial nucleic acids; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect antimicrobial- resistant pathogens. It also provides Acuitas MDRO Gene Test, Acuitas CR Elite Test, and Acuitas Resistome Test that are CLIA lab-based tests, which provide a profile of MDRO resistant genes for surveillance and response to outbreaks. In addition, the company offers Acuitas Lighthouse bioinformatics systems, which are cloud-based HIPAA compliant bioinformatics offerings that combine clinical lab test results with patient and hospital information, and provide analytics to enable manage MDROs in the hospital and patient care environment. Further, it engages in the development of Acuitas Rapid Test designed to detect urinary tract infection. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.
Recent Trading Activity for OpGen Inc (NASDAQ:OPGN)
Shares of OpGen Inc closed the previous trading session at 1,07 −0,030 2,73 % with shares trading hands.